Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Diagnos Laboratorium Utama Tbk's EBIT per Share for the
six
months ended in . 20 was Rp0.00.
PT Diagnos Laboratorium Utama Tbk does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in . 20.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PT Diagnos Laboratorium Utama Tbk's EBIT per Share or its related term are showing as below:
ISX:DGNS's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 13.1 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PT Diagnos Laboratorium Utama Tbk EBIT per Share Related Terms
PT Diagnos Laboratorium Utama Tbk EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diagnos Laboratorium Utama Tbk EBIT per Share Chart
PT Diagnos Laboratorium Utama Tbk Annual Data
Trend
EBIT per Share
PT Diagnos Laboratorium Utama Tbk Semi-Annual Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) has a EBIT per Share of Rp as of . 20. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Diagnos Laboratorium Utama Tbk and its competitors. According to the industry distribution chart, PT Diagnos Laboratorium Utama Tbk ranks #999999 out of 164 companies in the Medical Diagnostics & Research industry.
Is PT Diagnos Laboratorium Utama Tbk's EBIT per Share too high?
PT Diagnos Laboratorium Utama Tbk's current EBIT per Share is Rp. Based on the distribution chart, PT Diagnos Laboratorium Utama Tbk ranks #999999 out of 164 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, PT Diagnos Laboratorium Utama Tbk has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does PT Diagnos Laboratorium Utama Tbk's EBIT per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Diagnos Laboratorium Utama Tbk ranks #999999 out of 164 companies for EBIT per Share. This places PT Diagnos Laboratorium Utama Tbk in the lower half of its industry. The industry median EBIT per Share is 13.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.10, based on 164 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Diagnos Laboratorium Utama Tbk and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Diagnos Laboratorium Utama Tbk's current EBIT per Share is Rp. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Diagnos Laboratorium Utama Tbk stock overvalued right now?
PT Diagnos Laboratorium Utama Tbk (ISX:DGNS) has a current EBIT per Share of Rp. The current EBIT per Share is Rp. PT Diagnos Laboratorium Utama Tbk's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PT Diagnos Laboratorium Utama Tbk (ISX:DGNS), the current EBIT per Share is Rp as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Diagnos Laboratorium Utama Tbk operates in the field of Health Support Services and Private Clinic Activities. It provides health support service activities managed by both the government and the private sector, such as health laboratories in the form of X-Ray Laboratories, and other diagnostic imaging centers, as well as blood testing, private clinics, pharmaceutical warehouses, eye banks, blood banks, sperm banks, organ transplant banks, and other medical support services. Its products and services include Clinical Pathology Laboratory, Anatomical Pathology Laboratory, Genomics Laboratory, Homecare Health Services, Corporate Health Services, Microbiology Laboratory, and Research Services.
21GF Score
Get the complete analysis for ISX:DGNS
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:DGNS has been successfully added to your 
